Literature DB >> 11104032

Microdissection, DOP-PCR, and comparative genomic hybridization of paraffin-embedded familial prostate cancers.

P C Verhagen1, X L Zhu, L R Rohr, L A Cannon-Albright, S V Tavtigian, M H Skolnick, A R Brothman.   

Abstract

There is a clear genetic component to prostate cancer susceptibility. Regions reported to be linked to prostate cancer include 1q24-25 (HPC-1), 1q42.2-43, and Xq27-28. There is limited genetic information on familial prostate tumors. We used the Utah Population Database to identify familial prostate cancer cases and selected 35 cases from high-risk families. Tissue blocks containing discernable tumor were available from 19 cases; 13 of these yielded adequate specimens for analysis. Six cases came from families with linkage to HPC-1, 3 were known to have linkage to Xq27-28, and 4 had no linkage to a known locus; 7 cases were analyzed from patients who showed no known linkage (sporadic tumors) as controls. These paraffin-embedded tumors were laser microdissected, degenerate oligonucleotide (DOP)-amplified, and labeled for fluorescence detection by comparative genomic hybridization (CGH). Loss of 7q, 10q, and 16q and gain of 8q were common abnormalities present in both familial and sporadic tumors. Distinctive abnormalities included loss of 3p12-3p22 in 3 of 6 HPC-7-linked cases and in 2 of 3 X-linked cases and gain of 6q11-6q21 in 2 each of HPC-1 and X-linked tumors. In conclusion, laser microdissection, DOP-PCR, and CGH is a feasible method for analysis of paraffin-embedded prostate tumors. This study provides preliminary data suggesting that familial prostate cancer harbors some unique genetic changes when compared with sporadic prostate tumors.

Entities:  

Mesh:

Year:  2000        PMID: 11104032     DOI: 10.1016/s0165-4608(00)00276-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

Review 1.  Genetic susceptibility to prostate cancer: a review.

Authors:  Bas A J Verhage; Lambertus A L M Kiemeney
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

Review 2.  Advanced molecular cytogenetics in human and mouse.

Authors:  Kathleen Dorritie; Cristina Montagna; Michael J Difilippantonio; Thomas Ried
Journal:  Expert Rev Mol Diagn       Date:  2004-09       Impact factor: 5.225

Review 3.  [Laser microdissection in the molecular oncology of prostate cancer].

Authors:  N Wernert
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

4.  Comparison of whole genome amplification methods for analysis of DNA extracted from microdissected early breast lesions in formalin-fixed paraffin-embedded tissue.

Authors:  Nona Arneson; Juan Moreno; Vladimir Iakovlev; Arezou Ghazani; Keisha Warren; David McCready; Igor Jurisica; Susan J Done
Journal:  ISRN Oncol       Date:  2012-03-14

5.  FGF8 isoform b expression in human prostate cancer.

Authors:  V J Gnanapragasam; M C Robinson; C Marsh; C N Robson; F C Hamdy; H Y Leung
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

6.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Authors:  M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.